|
Excitement Over CAR-Engineered T-cells in Leukemia and Lymphoma
Medscape This was a patient who had undergone 10 prior therapies, including many different combinations of rituximab plus chemotherapy regimens, and the disease progressed a month after chemotherapy finished, so she was “clearly refractory,” he said. “Our data … Treated T-cells induce remissions in chemo-refractory B-cell lymphomasThe Oncology Report |
Age barrier falls for half-matched bone marrow transplantsThe Oncology ReportNo prior autologous BMT was allowed and post-BMT rituximab (Rituxan) was used in 55 of 126 patients with B-cell lymphoma. Patients in their 50s, 60s, and 70s had similar estim…
Dr. Brown on Idelalisib Plus Rituximab in CLLOncLiveJennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the development of the novel PI…
Treated T-cells induce remissions in chemo-refractory B-cell lymphomasThe Oncology ReportOne patient who, despite having undergone 10 prior therapies — including 3 rituximab-based chemotherapy regimens — continued to have lymphoma involvement of the …
|
Sequenta’s ClonoSIGHT MRD Test Can Detect Relapse of Diffuse Large B-Cell …
Fort Mills Times The study analyzed samples from 80 previously untreated DLBCL patients who received DA-EPOCH therapy with or without rituximab. Ten of the patients eventually progressed after initially achieving CR. Additional data demonstrating the utility of the … |
|
Sequenta’s ClonoSIGHT MRD Test Can Detect Relapse of Diffuse Large B-Cell …
HispanicBusiness.com The study analyzed samples from 80 previously untreated DLBCL patients who received DA-EPOCH therapy with or without rituximab. Ten of the patients eventually progressed after initially achieving CR. Additional data demonstrating the utility of the … |
Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin …Business Wire (press release)Infinity is currently enrolling patients in DYNAMO, a Phase 2 study evaluating the safety and efficacy of IPI-145 in approximately 120 patients wit…
Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B …MarketWatchAn investigator-sponsored Phase 1b, open-label study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination with rituximab (a monoclonal an…
|
Major Studies, Novel Talks Highlight ASH
MedPage Today Another presentation will reveal final results from a large, international phase III trial to compare obinutuzumab (Gazyva) and rituximab (Rituxan), each paired with chlorambucil, in patients with CLL and significant comorbid medical conditions. “Both … |
Orphan Drug Designations, Invitations to Investors Conferences, and Stock …EIN News (press release)… Administration (FDA) has granted orphan drug exclusivity for TREANDA all through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that …